Proprietary Technology

NeoVAC, aimed to enter the clinic in 2020, is developed utilizing an array of unique and proprietary technologies, which include the following:

PersoVAC™ – our personalised cancer vaccines containing patient- and tumor-specific neoantigens to treat cancer and prevent recurrence

AmpliVax™ – our proprietary DNA vaccine production platform featuring cell-free, synthetic, highly pure DNA vaccines which are rapid, scalable & affordable

PyroVant™ – our proprietary genetic adjuvant which encodes an immune stimulator, co-expressed with tumor-specific antigens to boost and focus the immune response to these antigens

CADVax™ – our proprietary in-house developed bioinformatics platform to optimize DNA vaccine design with more than 20 different antigens.